The bill inserts a new section into the Public Health Service Act establishing the Advisory Committee on Immunization Practices (ACIP) in statute, assigning it explicit duties on vaccine recommendations, pediatric vaccine lists for the Vaccines for Children (VFC) program, and regular reporting channels to HHS and Congress. It also authorizes support and operating funds for the committee.
Separately, the bill amends the National Vaccine Injury Compensation Program to require that any removal or modification of entries on the Vaccine Injury Table be supported by a preponderance of the best available scientific evidence. Together, these changes elevate procedural formality and transparency around federal vaccine policy and the legal standard for certain changes to compensation listings.
At a Glance
What It Does
Codifies ACIP as a statutory advisory committee under a new section of the Public Health Service Act, gives ACIP explicit duties to develop immunization recommendations and the list of pediatric vaccines for the VFC program, and requires the Department of Health and Human Services to use that list for VFC purchases and administration. It imposes an evidence standard for ACIP recommendations—requiring a preponderance of the best available, peer-reviewed scientific evidence—and sets deadlines and publication and congressional-notification requirements when CDC declines to adopt ACIP recommendations. The bill also amends the Vaccine Injury Table rules so removals or other substantive modifications must be supported by the same evidentiary standard.
Who It Affects
CDC and HHS leadership (Director, Assistant Secretary for Health, CMS Administrator) and the existing ACIP process; pediatric vaccine delivery via the Vaccines for Children program; health insurers and group health plans because ACIP recommendations drive coverage under existing law; vaccine manufacturers who will see formal timelines and congressional reporting tied to licensure and recommendation processes; and claimants and administrators of the National Vaccine Injury Compensation Program because the bill changes the evidentiary prerequisite for amending the Injury Table.
Why It Matters
By moving ACIP from an advisory practice to a statutory committee with defined processes, the bill makes vaccine policy more procedurally anchored—shortening some timelines, formalizing membership selection and reporting, and increasing transparency to Congress. The matching evidentiary requirement in the Vaccine Injury Table change raises the legal and scientific threshold for removing entries, which could make reverse adjustments harder and affect compensation dynamics.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The legislation creates a new, named statutory section for the Advisory Committee on Immunization Practices inside the Public Health Service Act. Rather than an informal advisory body, ACIP will be governed by the statutes that apply to federal advisory committees, receive designated agency support, and have its duties and reporting lines spelled out in law.
The bill directs ACIP to prepare vaccine recommendations and the pediatric vaccine list used for the Vaccines for Children program, and requires the Department to use that list for purchasing and administering pediatric vaccines under VFC.
Operational rules in the bill focus on governance: the Comptroller General supplies recommended candidates, the Secretary appoints between 15 and 19 voting members (with a 7-year chair term), and six federal agency officials serve ex‑officio without vote. A full-time or permanent part-time Designated Federal Officer (DFO) must be assigned from CDC leadership; the DFO runs meeting logistics, ensures procedural compliance with agency rules, and can chair or adjourn meetings as necessary.
The statute requires minimum meeting frequency and allows subcommittees, but keeps subcommittee work flowing back through ACIP rather than directly to HHS.The bill also prescribes records and public-access rules for committee materials and authorizes an external agreement with the National Academies for technical support. It allocates specific funding to cover operating costs and member compensation for a multi‑year period.
Finally, the measure amends the National Vaccine Injury Compensation Program to require a specified evidentiary standard before the Vaccine Injury Table is narrowed or otherwise materially changed, which affects the administrative and legal framework for adjusting compensable conditions.
The Five Things You Need to Know
The bill requires ACIP membership to be between 15 and 19 voting members, appointed from candidates recommended by the Comptroller General, with six named ex‑officio federal participants.
The chairperson’s term is set at seven years; other appointed members serve overlapping four‑year terms and may remain up to 180 days past term expiration if a successor is not in place.
ACIP must establish and periodically review the pediatric vaccine list used by the Vaccines for Children program; HHS must use that list for purchasing and administration activities under VFC.
The statute requires a permanent full‑time or permanent part‑time Designated Federal Officer from CDC to manage ACIP meetings, agendas, and procedural compliance and authorizes external support from the National Academies.
Congressional budget language: the bill authorizes $2,800,000 per year for each fiscal year 2026 through 2029 for ACIP operating costs, member compensation, travel, and staff support.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Statutory establishment and scope of ACIP
This is the core codification: it takes the long-standing ACIP and creates a named statutory section with explicit jurisdiction over vaccine recommendations in the civilian population. The practical effect is to move ACIP into the roster of formal federal advisory committees, subjecting it to the procedures and records requirements of chapter 10 of Title 5 and making HHS use the committee’s pediatric vaccine list for VFC purchasing and delivery.
Recommendation process and review pathway
This subsection assigns ACIP the duty to make vaccine use recommendations and directs the CDC Director to review and either adopt or publish the basis for not adopting those recommendations. The provision ties ACIP advice to an explicit evidentiary framework and builds in publication and congressional notification triggers when CDC departs from committee recommendations, increasing administrative transparency and creating predictable steps for adoption or disputation.
Duties, VFC integration, and administrative support
These paragraphs detail the content ACIP must cover (population groups, contraindications, adverse events) and give the committee responsibility for the VFC pediatric vaccine list. They direct the Office of the Director within the National Center for Immunization and Respiratory Diseases to provide management and permit ACIP to contract for outside support. The statute also sets recordkeeping expectations and makes the committee report to CDC leadership and other HHS officials, anchoring ACIP recommendations into operational programs like VFC and existing coverage rules.
Meetings, membership, and conflict/quorum rules
The bill prescribes minimum meeting frequency (at least three times a year), special timelines around vaccine licensure, and who qualifies as voting and non‑voting members. It requires Comptroller General recommendations for candidates, sets terms, defines a quorum as two‑thirds of voting members, and gives the DFO authority to temporarily designate ex‑officio members as voting members to address conflicts or absences. These mechanics affect how rapidly ACIP can form and decide recommendations and who ultimately shapes committee composition.
Vaccine Injury Table evidentiary standard
This amendment adds a requirement that any removal or substantive modification of entries on the Vaccine Injury Table be supported by a preponderance of the best available scientific evidence regarding vaccine safety or efficacy. While the Secretary retains authority to add new vaccines to the table, narrowing or removing items now carries an express evidentiary hurdle that will affect administrative reviews and potential litigation strategies.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Pediatric vaccine programs and clinicians — A statutory VFC list and clear integration into purchasing streamlines which pediatric vaccines are prioritized for federally funded distribution, reducing ambiguity about supply and administration policy.
- Public health planners and state health departments — Codified meeting minimums, reporting lines, and access to ACIP records provide predictable schedules and documentation to plan immunization campaigns and integrate federal guidance.
- Patients and prospective claimants to the NVICP — Raising the evidentiary bar for removing items from the Vaccine Injury Table provides a more stable set of compensable conditions and reduces the chance of abrupt narrowing of coverage.
- Researchers and scientific advisors — The bill explicitly prioritizes peer‑reviewed scientific evidence and enables formal external support arrangements (e.g., National Academies), strengthening pathways for research to inform policy.
- Insurers and plan administrators — Clear statutory linkage between ACIP recommendations and coverage obligations under existing law reduces ambiguity about what preventive services must be covered.
Who Bears the Cost
- CDC and HHS operational units — New procedural, reporting, and recordkeeping obligations, plus the need to staff a permanent DFO and support ACIP logistics, raise administrative workload even with an appropriation authorized.
- Vaccine manufacturers — Faster statutory timelines around ACIP consideration after licensure and intensified scrutiny tied to explicit evidentiary standards could mean quicker congressional visibility on recommendation disputes and potential market impacts.
- NVICP administrators and litigants — The preponderance requirement for table removals could increase the volume and complexity of scientific reviews and challenges when petitioning to change the Table.
- Comptroller General / GAO — The GAO is tasked with recommending candidates for appointment, adding a recurring administrative role and potential resource implications for candidate vetting.
- Stakeholder organizations designated as liaisons — Inclusion on a long list of named stakeholder groups formalizes their involvement but also requires time to engage in meetings, materials review, and liaison activity.
Key Issues
The Core Tension
The central tension is between anchoring vaccine policy in a visible, evidence‑based statutory process to increase stability and accountability, and preserving the speed, flexibility, and technical discretion public health agencies need to respond to emerging science and emergencies; transparency and higher evidentiary bars can strengthen trust and legal defensibility but can also slow or politicize decisions where rapid action is required.
The bill attempts to lock scientific standards and procedural transparency into statute, but that approach creates implementation choices that the text does not fully resolve. For example, the mandated reliance on "peer‑reviewed" evidence raises practical questions about how to weigh high‑quality real‑world evidence, industry data, or prepublication findings—especially for new products or during emergencies when peer review lags.
The statute also centralizes candidate selection through Comptroller General recommendations; that increases vetting but may slow appointments or narrow the pool in ways the bill does not address.
On the Vaccine Injury Table side, requiring a preponderance of the best available scientific evidence before removing items will make narrowing the table more rigorous, but it does not define how to weigh heterogeneous evidence streams or resolve conflicts between epidemiologic signals and mechanistic findings. The short deadlines and mandatory reporting to Congress when CDC departs from committee advice increase transparency but also create a near‑real‑time political spotlight that could influence technical deliberation or motivate legal challenges immediately after administrative decisions.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.